9.40

22.88% +1.75

After Hours: 9.36 -0.04 -0.43%

IGM Biosciences Inc (IGMS)

Overview News Price History Option Chain Discussions Forecast

IGM Biosciences Inc stock is currently priced at $9.40, with a 24-hour trading volume of 468.92K. It has seen a +22.88% increased in the last 24 hours and a +8.29% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $7.27 pivot point. If it approaches the $9.51 resistance level, significant changes may occur.

Previous Close:

$7.65

Open:

$7.74

24h Volume:

468.92K

Market Cap:

$552.59M

Revenue:

$2.13M

Net Income/Loss:

$-246.42M

P/E Ratio:

-1.7837

EPS:

-5.27

Net Cash Flow:

$-204.61M

1W Performance:

+30.56%

1M Performance:

+8.29%

6M Performance:

+112.67%

1Y Performance:

-13.60%

1D Range:

$7.41

$9.48

52W Range:

$3.81

$17.70

IGM Biosciences Inc Stock (IGMS) Company Profile

Name

IGM Biosciences Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

650-965-7873

Address

325 East Middlefield Road, Mountain View

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

IGMS's Discussions on Twitter

IGM Biosciences Inc Stock (IGMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-22	Resumed	Jefferies	Buy
Oct-17-22	Initiated	JP Morgan	Neutral
Aug-29-22	Initiated	BofA Securities	Buy
Dec-13-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-05-21	Upgrade	Wedbush	Neutral → Outperform
Aug-26-21	Initiated	Morgan Stanley	Overweight
Jan-29-21	Initiated	RBC Capital Mkts	Outperform
Jan-19-21	Reiterated	H.C. Wainwright	Buy
Dec-22-20	Downgrade	Wedbush	Outperform → Neutral
Jul-17-20	Initiated	Robert W. Baird	Outperform
Jul-01-20	Initiated	H.C. Wainwright	Buy
May-28-20	Initiated	SunTrust	Buy
Apr-22-20	Initiated	Wedbush	Outperform
Oct-14-19	Initiated	Guggenheim	Buy
Oct-14-19	Initiated	Jefferies	Buy
Oct-14-19	Initiated	Piper Jaffray	Overweight
Oct-14-19	Initiated	Stifel	Buy

View All

IGM Biosciences Inc Stock (IGMS) Latest News

IGM Biosciences Inc Stock (IGMS) Financials Data

IGM Biosciences Inc (IGMS) Revenue 2024

IGMS reported a revenue (TTM) of $2.13 million for the quarter ending December 31, 2023.

IGM Biosciences Inc (IGMS) Net Income 2024

IGMS net income (TTM) was -$246.42 million for the quarter ending December 31, 2023, a -11.45% decrease year-over-year.

IGM Biosciences Inc (IGMS) Cash Flow 2024

IGMS recorded a free cash flow (TTM) of -$204.61 million for the quarter ending December 31, 2023, a -1,174% decrease year-over-year.

IGM Biosciences Inc (IGMS) Earnings per Share 2024

IGMS earnings per share (TTM) was -$4.78 for the quarter ending December 31, 2023, a +10.99% growth year-over-year.

IGM Biosciences Inc Stock (IGMS) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
BAKER BROS. ADVISORS LP	Director	Mar 27 '24	Buy	9.24	27,844	257,170	3,664,073
BAKER BROS. ADVISORS LP	Director	Mar 26 '24	Buy	8.26	270,000	2,230,767	3,638,533
Schwarzer Fred	CEO AND PRESIDENT	Mar 14 '24	Sale	10.17	4,182	42,533	216,651
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 14 '24	Sale	10.17	2,543	25,864	90,418
Takimoto Chris H	CHIEF MEDICAL OFFICER	Mar 14 '24	Sale	10.17	2,535	25,782	94,388
Keyt Bruce	CHIEF SCIENTIFIC OFFICER	Mar 14 '24	Sale	10.17	1,844	18,754	171,856
Decker Lisa Lynn	CHIEF BUSINESS OFFICER	Mar 14 '24	Sale	10.17	1,578	16,049	61,006
Weber Steven	PRINCIPAL ACCOUNTING OFFICER	Mar 14 '24	Sale	10.17	464	4,719	26,507
Schwarzer Fred	CEO AND PRESIDENT	Mar 13 '24	Sale	9.88	4,765	47,055	220,833
Tahir Misbah	CHIEF FINANCIAL OFFICER	Mar 13 '24	Sale	9.88	2,897	28,608	92,961

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.